

January 11, 2011

Press Release

[Mitsubishi Tanabe Pharma Corporation](#)

"Kremezin®", Drug for Chronic Renal Failure Transfer of Marketing Rights in Japan

Osaka, Japan, January 11, 2011---Mitsubishi Tanabe Pharma Corporation (President & CEO: Michihiro Tsuchiya) announced today that following the expiration of the sub-license agreement executed between the Company and Daiichi Sankyo Company, Limited (hereinafter, "Daiichi Sankyo"), which grants Daiichi Sankyo exclusive rights in Japan to market Kremezin®, a drug for chronic renal failure, the marketing rights shall be transferred from Daiichi Sankyo to the Company as of April 1, 2011, and Mitsubishi Tanabe will market Kremezin® Capsules 200 mg and Kremezin® Fine Granules 2 g.

Kremezin® is an oral adsorptive charcoal, discovered by KUREHA CORPORATION, consisting of porous spherical activated carbon of high purity. It adsorbs uremic toxins secreted in the gastrointestinal tract or produced in the intestinal tract and excretes the toxins out of the body with the feces. This function of Kremezin® is effective in improving symptoms of uremia and delaying the introduction of dialysis treatment. Kremezin® was introduced to the Japanese market in 1991 as the first pharmaceutical drug in the world for proactive treatment of chronic renal failure (progressive). To this day, it has since established a strong position in the field of treatment of chronic kidney diseases.

In November 2006, the Company acquired exclusive rights to develop and market Kremezin® in the U.S. and Europe. Under the development code "MP-146," the product is currently in phase 3 clinical studies both in the U.S. and Europe.

Mitsubishi Tanabe Pharma continues to provide information on Kremezin® appropriately in Japan and strives to ensure high quality and stable supply of Kremezin® to contribute to patients and medical professionals.

< For inquiries, contact >
Corporate Communications Department
Tel: +81-6-6205-5211